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ABSTRACT 
Association of Mycobacterium avium subspecies paratuberculosis (MAP) with 
Crohn’s disease (CD) and not with ulcerative colitis (UC), two forms of inflammatory 
bowel disease (IBD), has been vigorously debated in recent years. This theory has been 
strengthened by recent culture of MAP from breast milk, intestinal tissue and Blood from 
patients with active Crohn’s disease. Culture of MAP from clinical samples remained 
challenging due to the fastidious nature of MAP including its lack of cell wall in infected 
patients. The advent of real time PCR has proven to be significant in infectious disease 
diagnostics.  In this study, real time reverse transcriptase PCR (RT-PCR) assay based on 
targeting mRNA of the IS900 gene unique to MAP has been developed. All variables 
included in RNA isolation, cDNA synthesis and real time PCR amplification have been 
optimized. Oligonucleotide primers were designed to amplify 165 bp specific to MAP 
and the assay demonstrated sensitivity of 4 genomes per sample. In hope this real time 
RT-PCR may aid in the detection of viable MAP cells in Crohn’s disease patients, a total 
of 45 clinical samples were analyzed. Portion of each sample was also subjected to 12 
weeks culture followed by standard nested PCR analysis. The samples consisted of 17 
cultures (originated from 13 CD, 1 UC and 3 NIBD subjects), 24 buffy coat blood 
(originated from 7 CD, 2 UC, 11 NIBD and 4 healthy subjects) and 4 intestinal biopsies 
from 2 CD patients. Real time RT-PCR detected viable MAP in 11/17 (65%) of 
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suspected cultures compared to 12/17 (70%) by nested PCR including 77% and 84% 
from CD samples by both methods, respectively. Real time RT-PCR detected MAP RNA 
directly from 3/7 (42%) CD, 2/2 (100%) UC and 0/4 healthy controls similar to results 
following long term culture incubation and nested PCR analysis. Interestingly, real time 
RT-PCR detected viable MAP in 2/11 (13%) compared to 4/11 (26%) by culture and 
nested PCR in NIBD patients. For tissue samples, real time RT-PCR detected viable 
MAP in one CD patient with the culture outcome remains pending.  This study clearly 
indicates that a 12-hr real time RT-PCR assay provided data that are similar to those from 
12 weeks culture and nested PCR analysis. Consequently, use of real time In our 
laboratory, we previously demonstrated a possible downregulation in the Interferon-
gamma receptor gene (IFNGR1) in patients with active Crohn’s disease using microarray 
chip analysis. In this study, measurement of RNA by real time qRT-PCR indicated a 
possible downregulation in 5/6 CD patients compared to 0/12 controls. The preliminary 
data suggest that downregulation in INFGR1 gene, and the detection of viable MAP in 
CD patients provides yet the strongest evidence toward the linkage between MAP and 
CD etiology.  
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CHAPTER ONE: INTRODUCTION 
        Crohn’s disease (CD) is known to be an important cause of gastrointestinal disease 
worldwide but occurring more frequently in the United States, United Kingdom and 
Scandinavia (19). CD can affect any part of the gastrointestinal tract; inflammation is 
discontinued in form of patches and transmural resulting in fistula formation, the most 
common location is the ileum and small bowel (32). CD is present in two distinct forms: 
perforating and non-perforating in clear analogy to two other mycobacterial diseases, 
leprosy and tuberculosis (27, 33, 43). The etiology of CD remains unknown; however 
granuloma and pathologic manifestations resemble aspects found in mycobacteria-caused 
diseases such as tuberculosis, leprosy and paratuberculosis (16, 27, 53, 8). 
        Mycobacterium avium subspecies paratuberculosis (MAP) has been reported as 
possible causative agent for CD, due to the very important similarities in symptoms and 
aspect of the disease with Johne’s disease, an inflammatory bowel disease in ruminants 
caused by MAP; Association of Map with CD was first sighted by Dalziel in 1913 and 
has got more attention recently when MAP was isolated from blood, gut, lymphoid tissue, 
and milk of CD patients (7, 46, 47). 
        MAP is a member of the Mycobacterium avium complex (MAC), it is well 
characterized by its acid fastness, slow growing rate and resistance to acid and alcoholic 
treatments (14) as well as to regular pasteurization techniques this meanly due to their 
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cell-wall rich in lipid and long chain peptidoglycans. MAP is considered very fastidious 
and requires long-term incubation during primary isolation from animal and human 
sources (47, 48, 52).  
        The role of MAP in CD has been controversial and was debated vigorously; 
isolation of MAP from clinical samples of CD patients has been inconsistent adding to 
the controversy. This is mainly due to the fastidious nature of MAP, its presence in 
Spheroplastic form in CD patients and to its slow growing nature, culture of MAP from 
clinical samples may take between 12 and 52 weeks. A new strategy of study is needed to 
investigate the role of MAP in CD etiology.   
        It had been reported that mutations in NOD2/ CARD15 gene are associated 
exclusively with CD (31; 35, 49) identifying the gene as the first susceptibility gene for 
Crohn’s disease NOD2 is expressed as cytoplasmic protein in monocytes, and includes a 
C-terminus leucine-rich repeat (LRR) domain that senses muramyl dipeptide (MDP), the 
minimal motif of bacterial cell wall peptidoglycan, suggesting a role for intracellular 
pathogen-host interactions in the etiology of the disease. 
        In previous study, An RNA Microarray analysis of the expression profile of genes 
from CD and UC patients using the buffy coats from peripheral blood had shown that 
IFNGR1 (interferon-gamma receptor) gene, which encodes the ligand-binding chain of 
the IFN-gamma receptor, is Downregulated exclusively in CD patients. Early studies had 
shown that deficiencies in IFNGR1 gene are associated with familial disseminated 
atypical mycobacterial infection and disseminated BCG infection. Individuals carrying 
these deficiencies have an immunologic defect predisposing them to infection with 
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mycobacteria (38, 39, 40). 
        In this study, we developed a novel real time RT-PCR to detect the presence of 
viable MAP in blood samples from patients with CD, UC, NIBD and healthy controls as 
described in Chapter 1.  In chapter 2, these clinical samples were subjected to INFGR1 
gene analysis using quantitative real time RT-PCR to evaluate the expression of IFNGR1 
gene in an attempt to confirm the Microarray findings.  Ultimately the study will provide 
for the first time weather there is a link between the INFGR gene downregulation and 
susceptibility to MAP infection in patients with active Crohn’s disease. If confirmed our 
finding will add a strong argument to the role of MAP in CD etiology. 
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CHAPTER TWO: RT-PCR FOR DETECTION OF VIABLE 
MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS 
IN BLOOD AND TISSUE FROM PATIENTS WITH CROHN’S 
DISEASE  
Summary 
 
        Association of Mycobacterium avium subspecies paratuberculosis (MAP) with 
Crohn’s disease (CD) and not with ulcerative colitis (UC), two forms of inflammatory 
bowel disease (IBD,) has been vigorously debated in recent years. This theory has been 
strengthened by recent culture of MAP from breast milk, intestinal tissue and Blood from 
patients with active Crohn’s disease. Culture of MAP from clinical samples remained 
challenging due to the fastidious nature of MAP including its lack of cell wall in infected 
patients. The advent of real time PCR has proven to be significant in infectious disease 
diagnostics.  In this study, real time reverse transcriptase PCR (RT-PCR) assay based on 
targeting mRNA of the IS900 gene unique to MAP has been developed. All variables 
included in RNA isolation, cDNA synthesis and real time PCR amplification have been 
optimized. Oligonucleotide primers were designed to amplify 165 bp specific to MAP 
and the assay demonstrated sensitivity of 4 genomes per sample. In hope this real time 
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RT-PCR may aid in the detection of viable MAP cells in Crohn’s disease patients, a total 
of 45 clinical samples were analyzed. Portion of each sample was also subjected to 12 
weeks culture followed by standard nested PCR analysis. The samples consisted of 17 
cultures (originated from 13 CD, 1 UC and 3 NIBD subjects), 24 buffy coat blood 
(originated from 7 CD, 2 UC, 11 NIBD and 4 healthy subjects) and 4 intestinal biopsies 
from 2 CD patients. Real time RT-PCR detected viable MAP in 11/17 (65%) of 
suspected cultures compared to 12/17 (70%) by nested PCR including 77% and 84% 
from CD samples by both methods, respectively. Real time RT-PCR detected MAP RNA 
directly from 3/7 (42%) CD, 2/2 (100%) UC and 0/4 healthy controls similar to results 
following long term culture incubation and nested PCR analysis. Interestingly, real time 
RT-PCR detected viable MAP in 2/11 (13%) compared to 4/11 (26%) by culture and 
nested PCR in NIBD patients. For tissue samples, real time RT-PCR detected viable 
MAP in one CD patient with the culture outcome remains pending.  This study clearly 
indicates that a 12-hr real time RT-PCR assay provided data that are similar to those from 
12 weeks culture and nested PCR analysis. Consequently, use of real time RT-PCR may 
be significant in investigating the controversial role of MAP in CD pathogenesis. 
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 Introduction 
 
        Mycobacterium Avium subsp paratuberculosis (MAP), a member of the 
Mycobacterium avium complex (MAC) belongs to the genus of Mycobacteria which is a 
large group of high %G+C gram positive microorganisms including more than a 100 
species. The mean characteristics of this bacterium is its acid fastness, slow growing rate 
and resistance to acid and alcoholic treatments (14) as well as to regular pasteurization 
techniques due to the complexity of their cell-wall rich in lipid and long chain 
peptidoglycans. Unlike other Mycobacteria, MAP is the only Mycobacterium subspecies 
that depend on the siderophore mycobactin for in vitro growth (9). MAP is considered 
very fastidious and requires long-term incubation during primary isolation from animal 
and human sources (47, 48, 52).    
        MAP is an opportunistic intracellular chronic pathogen, it was identified over 100 
years ago as the causative agent of Paratuberculosis in ruminants (21), known also as 
Johne’s disease (JD), an inflammatory disease that affect the gastrointestinal (GI) tract 
and manifest as a severe weight loss, diarrhea, decrease in milk production and ultimately 
may lead to the death of infected hosts (30). MAP infection in farm animals has great 
economic impact with an estimated three billions dollars loss per year world wide (6, 25). 
The resistance of MAP to standard pasteurization and its detection in drinking water have 
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alarmed Scientists of possible zoonotic potential and impact on humans. 
        The association of MAP with Crohn’s disease, a chronic inflammatory bowel 
disease with significant histological and pathological similarities with JD (18, 21) 
tuberculosis and sarcoidosis, has been suggested initially by Dalziel (16) but ruled out by 
Crohn’s et al (15) and reemerged again following the culture of Spheroplastic (cell wall 
deficient) form of MAP from mesenteric tissue from patients with Crohn’s disease 
following several months of culture incubation (7). The association of MAP with Crohn’s 
disease became more controversial due to the conflicting outcomes in all reported studies. 
However, Schwartz et al (54) reported the development of modified 7H9 culture media, 
known as Mycobacterial Growth Indicator Tube (MGIT) and the isolation of MAP from 
intestinal tissue from Crohn’s disease patients following 10-12 weeks of incubation. This 
was followed by the isolation of MAP from human milk (46) adding more evidence to 
the similarity between MAP infection in animals and human hosts. The use of MGIT 
culture media for rapid isolation and detection of MAP from human sources has been 
recently confirmed by investigators in the United Kingdom (3) and most recently in the 
united state. World-wide Interest in investigating MAP association in Crohn’s disease 
pathogenesis has been recently stirred following the report of isolation of MAP from 
human peripheral blood suggesting for the first time a bacteremic phase in Crohn’s 
disease pathogenesis and possible systemic infection in patients with MAP infection (47). 
        Numerous studies have been done in an attempt to determine the role of MAP in 
Crohn’s disease etiology, but the results were inconsistent which added to the 
controversy of the association of MAP with the disease. 
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        Due to the challenges in consistent detection of MAP in human clinical samples, 
some investigators relied on serologic detection of anti-MAP IgG antibodies in sera from 
Crohn’s disease patients. However, using Serological tests such as IDEXX which is 
based on cytoplasmic proteins from MAP cultured from JD-animal resulted in detection 
of anti-MAP IgG antibodies in sera from Crohn’s disease patients similar to sera from 
patients with ulcerative colitis and normal controls (11). However, when recombinant 
MAP proteins such as p35 and p36 proteins were used in an ELISA-based assay, MAP 
antibodies were detected in the majority of sera from patients with Crohn’s disease and 
significantly less in sera from patients with ulcerative colitis and normal subjects (45).  
Most recently, MAP DNA has been detected directly in tissue samples from the majority 
of Crohn’s disease patients by FISH (51) and nested PCR (1).  
        Despite the success in detection of MAP, MAP DNA, or MAP antibodies in tissue 
or blood samples which added significant evidence toward MAP association in Crohn’s 
disease pathogenesis, many in the gastroenterology community remained skeptics and 
posted vigorous negative commentary (41, 43). The need for new methodology that can 
associate viable MAP with Crohn’s disease may be the key to providing key evidence to 
the link. In this study a reverse transcription (RT) PCR based on Oligonucleotides 
primers derived from the IS900 specific to MAP has been developed using real time 
PCR. This new and improved technology provides real time detection of MAP RNA 
(indicating viability) in clinical samples from humans infected with MAP. Ultimately, 
MAP can be detected, if present, in clinical samples with in 12 hours instead of 12 weeks 
of culture incubation.    
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Materiel and Methods 
 
        All materials used in this study were prepared and processed aseptically inside 
Biosafety cabinets dedicated for specific purpose.     
 
Bacterial strains: 
        Clinical MAP strain Ben obtained and purified from CD tissue was used in this 
study. Other microorganisms were also included such as Mycobacterium tuberculosis 
strain H37Ra (ATCC 25177), Mycobacterium avium subspecies avium, Mycobacterium 
smegmatis strain MC2155. All mycobacterial isolates were cultured in Bactec or the 
MGIT culture media. Supplements including OADC (oleic acid-albumin-dextrose-
catalase) and Mycobactin J (0.5 mg/mL) were added to media when MAP was cultured.  
Patients Populations: 
        A total of 24 subjects were included in the study: 7 with Crohn’s disease, 2 with 
ulcerative colitis, and 15 with non-inflammatory bowel disease (of which three were 
healthy controls). Informed consent was obtained in accordance with institutional review 
board regulations at the University of Florida, Gainesville Veterans Affairs Medical 
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Center, and the University of Central Florida. The diagnosis of Crohn’s disease or 
ulcerative colitis was established on standard clinical, endoscopic, histological, and 
radiographic criteria.  
Clinical Samples: 
        One 4-mL whole blood sample drawn into sterile K2-EDTA Vacutainer tube was 
obtained from every patient participating in the study. All samples were coded to conceal 
the patient’s identity and the diagnosis. The samples were immediately processed in a 
class II biosafety cabinet. The buffy coat layer from each tube was transferred into a 
separate sterile RNase free tube containing 750ul of RNA later solution (Ambion, 
California) and was used immediately for extraction of RNA. Surgically removed tissue 
specimens were also recruited and used in this study.  The tissue samples were stored in 
empty sterile tubes and coded as described earlier. All clinical samples were stored on ice 
and transferred to the laboratory with in 24 hours of collection. Blood and tissue samples 
were processed immediately either for culture in Bactec and MGIT media (Becton 
Dickinson) with supplements or used for direct isolation of RNA.   
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        Cultures: 
        Blood and tissue samples were cultured as described previously (47), a total of 14 
cultured samples suspected of mycobacterial growth were analyzed by extraction of RNA 
and real time RT-PCR analysis as described later. The concentration of microorganism 
cells used in the specificity experiments was estimated using spectrophotometric 
measurement of 500ul of each bacterial culture at O.D. 680 nm in Smartspec (BioRad, 
CA) 
 
RNA extraction: 
        Clinical MAP strain Ben was used in all experiments related to extraction of RNA, 
cDNA and PCR analysis. Extraction of RNA was performed using an RNA isolation kit 
from Qiagen (Qiagen, Valencia, CA) with some modifications as follows. A 500uL of 
MAP culture (0,58CFU/mL) was centrifuged at 13,000 rpm (17400g) at 4oC for 3min. 
Cell pellet was resuspended in 1 ml of lysis buffer. Cells were physically disrupted using 
Fast-prep system and pro blue cap tubes at speed of 6.5 m/s for two cycles with each 45 
Seconds (Qbiogene, CA). Cell lysate was then centrifuged at 13000 rpm (17400g) in 4 oC 
for 5 min Supernatant was removed to a sterile 2-ml RNase free tube followed by the 
addition of 1mL elution buffer. The mixture was poured into the column as described by 
the manufacturer. RNA in eluted buffer was then mixed with two volumes of ethanol, 
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stored at -20 oC for 2 hours. Tubes were then centrifuged at 13000rpm (17400g) at 4 oC 
for 15min. Nucleic acid pellet was then washed with 70% ethanol, dried in a speed 
vacuum (BioRad, Hercules, CA ) and finally dissolved in 50uL Of DEPC 
(Diethylpyrocarbonate) sterile water. DNA was removed by the addition of DNase 
(2units/ul) and incubation at 37 oC for 30min. DNA removal was confirmed by agarose 
gel electrophoresis. The concentrations of RNA solutions were measured at an O.D. 260 
nm.  
Reverse Transcription: 
        RNA extracted from MAP strain Ben was used as template during reverse 
transcription and cDNA analysis. Superscript III reduced RNase H activity (envitrogen, 
CA)  was used and we followed the protocol described in the kit with some 
modifications, we added 2pmole of oligonucleotide PrimersF1/R1, 200g of RNA and 
10mM of dNTP mix into a sterile PCR tube, the mixture was heated at 65oC for 5min and 
incubated on ice for 3min then we added the buffer, RNase inhibitor and the enzyme 
(200units), we incubated the reaction mixture at 60oC for 45min then at 70 oC for 15 min 
to inactivate the reaction. 
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Real time PCR: 
        cDNA obtained by reverse transcription was subject to real time PCR  using Syber 
green and MY IQ system (BioRad, Hercules, CA ).12.5ul of 2x SYBR Green (100mM 
KCl, 40 mM Tris-HCl, pH8.4, 0.4mM of each dNTP, enzyme(50units/ml, 6mM Mgcl2, 
SYBR Green I, fluorescein, and stabilizers) were added to sterile PCR tube as well as 
Betaine, oligonucleotide primers (6pM), 2.5ul of cDNA and sterile water for a final 
volume of 25ul.the PCR tubes were then subject to the following protocol:  hot start step 
of 5min at 95oC followed by20 sec at 95oC then 30 sec at 60oC for annealing, the 
fluorescence reading was done at this step. Two set of primers were used, the first 
set(Av1/Av2) amplify 280 base pair of MAP specific sequence IS900 and was used to 
generate the standards while the second set(F1/R1) amplify 165 base pair within the 280 
amplified by Av1/Av2 
      -    Av1: 5’ ATGTGGTTGCTGTGTTGGATGG 3’ 
- Av2: 5’CCGCCGCAATCAACTCCAG 3’ 
- F1: 5’ CACGTCGGCGTGGTCGTCT 3’ 
- R1: 5’ CGTCACCGCCGCAATCAACT 3’ 
        Optimization of our Real time PCR was done by determining the optimal 
concentration of primers, the optimal annealing temperature as well as by determining the 
MgCl2 concentration.   
13 
 
  
 
        Specificity: 
        Specificity was tested for F1/R1 Oligonucleotide primers using template from 
known bacteria; strains including Mycobacterium avium subspecies avium, 
Mycobacterium tuberculosis (strain H37 Ra, non virulent) and Mycobacterium smegmatis 
(strain MC2155).  
        Sensitivity: 
        MAP RNA was subjected to reverse transcription as described earlier. The standard 
PCR was performed  using Taq DNA polymerase Kit from eppendorf (Brinkman 
instruments, Westbury, NY) as follows: PCR reactions consisted of PCR buffer (20mM 
Tris-HCl pH8.0, 100mMKCl, 0.1 EDTA was added to a final concentration of 1X, 1mM 
DTT, 50% Glycerol, 0.5% tween 20, Betaine (0.5mM), MgCl2 (5mM), forward and 
reverse primers (F1/R1), 5ul cDNA  and sterile distilled water for a final volume of 50ul 
into sterile PCR tube. Tubes were incubated in iCycler system (BioRad, CA) for 5 min at 
95oC as hot start step, followed by 40 cycles composed each of denaturation phase at 
95o
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C for 30seconds, annealing phase at 60o oC for 45 seconds, and extension phase at 72 C 
for 1min, followed by an extension cycle for 10 min. Product was then purified using 
PCR purification kit (Qiagen, CA). Concentration was determined by absorbance reading 
at 260nm in nanodrop system (Nanodrop technologies, Wilmington, DE ) and subjected 
to a series of dilutions (1:1, 1:10, 1:100, 1:1000, 1:10000, 1:100000and 1:1000000) with 
  
 
an initial quantity of 33ng . Real time PCR was done using F1/R1 set of primers as 
described in Table 3 after optimization. 
Generating Standards for Real time RT_PCR: 
        These dilutions used in the sensitivity assay were later used as standards when 
applied this method to clinical samples and cultures. 
Melt Curve analysis: 
        Melt curve analysis was applied to all samples in order to exclude contamination in 
our study where the nature of the amplified sequence can be confirmed.  
        The reaction was carried out as follow: the PCR tubes containing real time RT-PCR 
products were incubated at 95oC for 1 minute followed by another minute at 60oC then 80 
cycles with incubation at variable temperature for 10 seconds each, temperatures varied 
between 65oC and 94oC with an increment of 0.5 oC.   
 
Results 
 
        Real time RT-PCR targets and amplifies RNA templates signaling viability of the 
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template source.  In this study we used RT-PCR based on oligonucleotide primers 
derived from the IS900 sequence which is unique to MAP. All parameters and variables 
involved in the isolation of RNA, synthesis of cDNA and PCR analysis were evaluated 
and finally optimized to provide sensitive and maximum specificity outcome. Initially, 
stock MAP culture was used to prepare MAP cultures in order to be used for RNA 
extraction which in turn was used in the evaluations of all parameters. 
RNA Extraction: 
        Due to the complexity of the cell wall of MAP and its absence in the MAP cell in 
human clinical samples, different RNA isolation methods were evaluated. Initially, an 
RNA isolation kit; RNA/DNA mini kit (Qiagen, CA); was used, the outcome was 
disappointing due to the lower yield of isolated RNA (Figure 1, lane 1). However, 
increasing the incubation period with lysosyme from 10 to 30 minutes and at 37 oC 
instead of room temperature resulted in significant and quality increase in the isolated 
RNA (Figure 1, lane 2). Further optimization of RNA isolation protocol had resulted in 
the development of a modified procedure based on the combination of chemical lysis and 
physical disruption of the MAP cells (Figure 1, lane 3).  Physical disruption was achieved 
using Fast-Prep Ribolyser (Qbiogene, CA). As shown in Figure 1, maximum RNA yield 
was obtained when the latter RNA isolation protocol (combined chemical and physical 
disruption treatment) was used (lane 4) compared to the protocol from Qiagen (Lane 1). 
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        Treatment with DNase for 30 min at 37oC resulted in complete DNA removal from 
the RNA extracts. This was confirmed following direct analysis of the RNA solution by 
agarose gel electrophoresis which resulted in absence of any DNA band (Figure 2). The 
purity of the RNA extracts was also confirmed by performing PCR analysis on the RNA 
extract without synthesis of cDNA template (Figure 3, lanes 1). The MAP target was 
amplified when the cDNA step was included but not when the cDNA synthesis was 
eliminated confirms the complete hydrolysis and removal of any DNA traces from the 
RNA extracts (figure 4). 
        RNA was quantified using spectrophotometric measurement and then stored at _80 
oC until use.         
 Optimization of the RT-PCR: 
        Primer Design:  MAP DNA consists of high percentage of G+C which is estimated 
to be 69%. This characteristic favors formation of secondary structures and may lead to 
false positive and lack of amplification. We used DNA folding software, available at 
http://www.bioinfo.rpi.edu/~zukerm/, to determine the right annealing temperature to 
minimize secondary structures of the template in order to design and evaluate 
Oligonucleotide primers specific to MAP. The AV1/AV2 Oligonucleotide primers (Table 
2) have been used successfully in our laboratory (3, 47, 51). Figure6 illustrates the 
structure of IS900 under different temperatures. We designed new Oligonucleotide 
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primers termed F1/R1 using the Primer 3 software available at 
http://frodo.wi.mit.edu/cgi-bin/primer3.  Blast analysis of the F1/R1 primers confirmed 
the theoretical amplification of MAP template only and provided poor identity with other 
genomes targets.  
        The optimal concentration of F1/R1 primers was determined by testing several 
dilutions of each primer. In this study, primer concentrations ranged from 1 pmole/ul to 
30pmole/ul were evaluated. As shown in Figure 7. Concentration of 6pmole/ul has been 
identified to be the optimal and provided best amplification. Additionally, 6 pmole/ ul 
resulted in significant reduction of primer dimerization even in negative controls (those 
tunes lacking any templates). 
        Annealing temperature: 
        Following primers design and the estimation of appropriate annealing temperature, 
we performed a temperature gradient assay on the MAP RNA template. As shown in 
Figure 8, the annealing temperature ranged from 54 oC to 64 oC with an increment of 1.2 
oC. Optimum amplification was detected at 58 oC and 60 oC. Due to the nature of high 
%G+C content of the MAP genome, we favored to use the 60 oC annealing temperature.   
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        Optimization of Magnesium ions:    
        The concentration of MgCl2 in PCR mixtures is known to play a major role in the 
level of the assay sensitivity. In this study, MgCl2 concentrations ranged from 0 uM to 30 
uM were evaluated. As shown in Figure 9, MgCl2 at 10 uM has been identified to provide 
the optimal amplification signal in a 50 ul PCR reaction.  
        Over All RT-PCR Protocol: 
        Following the evaluation of all variables included in this RT-PCR assay, we have 
developed and optimized protocol which is described in Table 3 
        Sensitivity of RT-PCR: 
        The optimized protocol described in Table 3 was employed on serial dilutions of 
MAP cDNA ranged from 33ng to 0.000033ng in order to determine the lowest 
concentration of RNA template needed for this assay. Figure 10 shows that MAP 
template was detected in PCR mixtures containing 33ng/ul, 3.3ng/ul, 330pg and 33pg. 
The lowest concentration of MAP template detected by this assay (33pg) corresponds to 
61 copy of the IS900 gene. MAP contains between 14 to18 copies of the IS900 indicating 
that this RT-PCR assay may be able to detect as low as 4 MAP cells per sample. 
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        Specificity of the RT-PCR: 
        In order to confirm the result of the Blast analysis of the Oligonucleotides primers 
used in this study, several bacterial isolates (Table1) have been cultured and prepared for 
extraction of RNA. RNA templates were then used for synthesis of cDNA and PCR 
analysis. As expected, only MAP template was detected. There was no amplification 
signal from all other microorganisms including the closely related M. avium subspecies 
avium (Figures 5). 
Clinical Evaluation of the RT-PCR assay 
        Since the ultimate application of this newly developed RT-PCR assay is to detect 
viable MAP in clinical samples in hope it will aid in rapid identification of viable MAP in 
clinical samples, we evaluated a total of 45 samples originated from subjects diagnosed 
with Crohn’s disease, ulcerative colitis and NIBD including healthy controls. All samples 
were blindly coded in order to conceal the identity and diagnosis of the sample. The 
diagnosis was revealed following the conclusion of all experiments. Of the 45 samples, 
17 were MAP cultures previously identified by acid-fast stain and nested PCR, 24 buffy 
coat preparations from peripheral blood samples and 4 tissue homogenates from fresh 
surgically removed tissue specimens. Tables 4 and 5 describe the clinical code of each 
sample, diagnosis and the nature of the sample. The 17 MAP cultures originated from 13 
patients with Crohn’s disease, 1 with Ulcerative colitis and 3 from NIBD subjects. The 24 
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buffy coats preparations consisted of 7 from Crohn’s disease patients, 2 from Ulcerative 
colitis patients and 15 from NIBD individuals. All 4 tissue samples were removed from 
two Crohn’s disease patients with each patient providing inflamed and normal tissue 
samples. Interestingly, patients who provided tissue samples have also provided 
peripheral blood samples.  
        MAP cultures: 
        Of the 17 cultures used in this study which originated from human sources, 12 
(70%) were confirmed to have MAP by conventional nested PCR. All 17 cultures were 
also evaluated using real time RT-PCR and 11 (65%) were also MAP positive. 
Interestingly, the 11 MAP cultures confirmed by real time RT-PCR were also MAP 
positive by conventional nested PCR (Table 4 a and b). Over all, 11/12 (92%) of the 
MAP confirmed culture using nested PCR were positive by our real time RT-PCR.        
 
        Peripheral Blood Buffy coats: 
        A total of 24 Buffy coats preparations originated from 7 CD, 2 UC and 15 NIBD 
subjects were evaluated using standard nested PCR and real time RT-PCR assay. By Real 
time PCR, a total of 7/24 (29%) were confirmed to have viable MAP. Of the 7 MAP 
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positive samples, 3/7 (43%) from CD, 2/2 (100%) from UC and 2/15 (13%) were from 
NIBD patients.  Using culture and nested PCR assay, a total of 9/24 (37%) was MAP 
positive, specifically, 3/7 (43%) from CD patients, 2/2(100%) from UC patients, and 4/15 
(26%) from NIBD subjects (Table 5a and b). It is important to note that both methods 
confirmed viable MAP in the same three samples from CD patients. Similar outcome 
were observed from samples originated from UC patients. However, of the 4 samples 
from NIBD subjects that were MAP positive by culture and nested PCR, only one was 
positive by our real time RT-PCR. The real time RT-PCR detected MAP in one NIBD 
sample that was negative by culture and nested PCR. 
        Tissue samples: 
        A total of 4 tissue samples from 2 CD patients (1 inflamed and 1 non-inflamed 
specimen from each patient) were evaluated by culture and nested PCR and real time RT-
PCR. Real time RT-PCR analysis detected MAP in 1/4 (25%) tissue samples. Results 
from the culture and conventional nested PCR are still pending (table 6). The detection of 
MAP in tissue by real time RT-PCR originated from inflamed lesion of CD patient. The 
non-inflamed tissue from this CD patient was negative for MAP using real time RT-PCR. 
Interestingly, blood sample from the same patient was also negative for MAP using real 
time RT-PCR indicating a non-systemic state of MAP infection in this CD patient.                                   
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Discussion 
 
        MAP has been confirmed to be the etiologic agent of JD. Its thermal tolerance, 
resistance to alcohol and acid treatment and survival in pasteurized milk add more 
characteristics to its pathogenicity and its virulence potential. As described earlier, MAP 
role in Crohn’s disease pathogenesis has been suggested and vigorously debated. 
Development of new methodology that facilitates rapid and consistent detection of MAP 
in clinical samples from humans with Crohn’s disease may assist in the elucidation of 
MAP role in Crohn’s disease. The development of RT-PCR assay is challenging due to 
several reasons. Of which, working with RNA is extremely tedious and when the number 
of bacterial cells such as MAP  in clinical samples is naturally low, it adds to the 
limitations of the assay. In this study, the RNA yield has been maximized and all 
precautions were enforced in order to maximize cell lysis and minimize RNA 
degradation. As shown earlier, a combination between chemical lysis and physical 
disruption of MAP cells resulted in maximum recovery of MAP RNA. The use of 
oligonucleotide primers derived from the IS900 of MAP added quality characteristic to 
this RT-PCR assay. This is due to the presence of about 17 copies of the IS900 genes in a 
single MAP cell which improves the sensitivity level by several folds.   
        The potential application of this RT-PCR assay in clinical diagnosis has been 
validated in this study following the analysis of a total of 45 samples originated from 
patients with Crohn’s disease, Ulcerative colitis and non-IBD subjects. In addition the 
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coding system enforced here, the majority of these samples were also analyzed in our 
laboratory for the presence of MAP using other methodology. Ultimately, this technology 
will aid other conventional techniques such as culture media, despite the need for long 
term incubation, in rapid detection of viable MAP. Most importantly, the application of 
this technology will significantly aid the elucidation of MAP role in Crohn’s disease 
pathogenesis. Regardless of the outcome, this test may aid in resolving the MAP debate 
in Crohn’s disease etiology. 
        Culture can be delicate, as M. paratuberculosis is a slow growing and has extremely 
long incubation times which can raise a contamination problem (2). Other diagnosis 
methods had shown specificity and viability issues (11), a conventional RT-PCR is hard 
to establish for detection of MAP in blood or tissue samples due to the small number of 
bacterium recovered from these samples (14), development of new Real time RT- PCR 
for detection of MAP in blood and tissue samples from Crohn’s disease patients may 
open a new horizons in establishing a link between MAP and this debilitating disease as 
well as in the diagnosis of the disease.  
        In this study, we have been able to extract MAP RNA from blood and tissue samples 
using a mechanical disruption of the cells combined with chemical extraction, which goes 
well with systemic nature of the disease (34, 47). The half life of RNA is markedly short 
and the presence of RNase in the cell extract render the extraction even more delicate 
(42), the use of RNase inhibitors in the extraction process and working at temperature 
relatively low helped increasing the RNA recovery. To avoid DNA contamination and 
ensure clean RNA, we treated the samples with DNase; RNA samples were used as 
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negative control for the Real time PCR to check for DNA contamination. 
        We used Real time RT-PCR for it is very sensitive, does not require as much time 
and to minimize the risk of contamination. Real-time RT-PCR has been recognized as an 
accurate and sensitive method of quantifying mRNA transcripts (17, 50). This method 
allowed us to detect accumulation of cDNA template in real time manner using SYBR 
Green as an intercalating dye, rather than by conventional end-point analysis. Also there 
is no need for post amplification procedures such as gel electrophoresis, analysis can then 
be completed rapidly.  
        Our study was based on amplification of region of the IS900 sequence unique for 
MAP using specific primers that amplify 165 base pair within the sequence as shown by 
the specificity assay. The concentration of primers was determined with regard to 
dimmers formation and optimal amplification of the template, in facts, primer dimmers 
are a very common issue for real time RT-PCR (4, 5, 50). The annealing temperature was 
determined with computational method that takes in consideration the percentage of base 
pairs, the thermodynamic of the sequence and the possible secondary structures that 
could be formed at each specific temperature, this had enable us to prevent any 
nonspecific annealing of primers and helped reduce the generating of secondary 
structures.  
        The sensitivity assay showed that our real time RT-PCR is able to detect as low as 
61 copy of the IS900 sequence corresponding to 4 genome copies of MAP, which can be 
of significance knowing that we are using cDNA as template and the number of 
bacterium per sample is usually low, in addition to the short period of time that it takes to 
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analyze the samples (less than 12 hours from the blood processing to real time RT-PCR 
analysis). This can make the real time RT-PCR an alternative way for detection of MAP 
in clinical samples from CD patients. Other studies using DNA based real time PCR were 
able to detect lower copies of the genomes that were interested in, for example Danbing 
Ke et all were able to detect 1 copy of the GBS genome (17). Our method is an RNA 
based method so we can go in harmony with the goal of our study which is the detection 
of viable MAP from clinical samples. 
        The application of our real time RT-PCR to buffy coat from inflammatory bowel 
disease patients and individuals with non-inflammatory bowel disease (NIBD) and its 
comparison with cultures of MAP from buffy coat and tissue samples from same patients 
had shown a concordance of the results and therefore gave more incredibility to our 
newly developed method. 54.5 % of IBD patients participating in this study are positive 
for MAP but only 12.6 % of the NIBD were positive, the 12.6% of NIBD could be 
exposed to MAP. In fact, MAP was isolated from water (41) and from pasteurized milk 
(24), other studies had found Map in NIBD control with hyperthyroid and diarrhea (3). 
Overall, this study show that real time RT-PCR could be an alternative way to detect 
MAP in Crohn’s disease patients, this method has an answer for the viability, specificity 
issues as well as for the long term incubation raised by other methods used to detect MAP 
in clinical samples. The 54.5% MAP positive patients is a significant percentage, but 
view the population studied, we still need to diagnose more samples in order to have a 
confirmed association of MAP with Crohn’s disease.  
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CHAPTER THREE: IFNGR1 GENE IS DOWNREGULATED IN 
PATIENTS WITH CROHN’S DISEASE: A MYCOBACTERIAL 
INFECTION? 
Summary 
 
        In our laboratory, we previously demonstrated a possible downregulation in the 
Interferon-gamma receptor gene (IFNGR1) in patients with active Crohn’s disease using 
microarray chip analysis. In this study, Measurement of RNA by real time qRT-PCR 
indicated a possible downregulation in 5/6 CD patients compared to 0/12 controls. Over 
all, a total of 5/6 (83%) CD patients have MAP infection and downregulation in the 
INFGR1 gene. The preliminary data suggest that downregulation in INFGR1 gene and 
the detection of viable MAP together in CD patients provide yet the strongest evidence 
toward the linkage between MAP and CD etiology. 
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 Introduction 
       
        In normal immune response to microbial infection, cascades of signaling pathways 
are initiated leading to activation of variety of types of immunity cells such as dendritic 
cells and macrophages (60, 63). In the presence of an initiating antigenic stimulus, 
antigen presenting cells (monocytes/ macrophages) produce IL-12 that stimulates TH-1 
lymphocytes to increase their IFN-gamma production that will then acts on infected 
macrophages to induce the production of proinflammatory cytokines, such as TNFalpha, 
IL-6 and IL-1beta, which are the direct cause of inflammation in CD (1,2). This signaling 
cascade leads macrophages to enhanced phagocytosis and intra-cellular killing of the 
antigen producing infectious agent and so to the elimination of the antigenic stimulus. 
However, if the immune system can not clear the antigen by this mechanism, either 
because of the quantity of the antigen or genetically determined dysfunction in 
production of cytokines and/or their respective receptors, a misdirected inflammatory 
situation is seen such is the case of atypical tuberculosis (48), leprosy or any other 
chronic infection with persisting antigenic burden. CD falls in the same category, in fact, 
patients with this disease present abnormality in their immune system, but it is not known 
yet whether these abnormalities are causes or results of the disease.  
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        CD and UC are known as important causes of gastrointestinal disease worldwide but 
occurring more frequently in the united state, United Kingdom and Scandinavia (19), it is 
known that Crohn’s disease affect 13 out of every 100,000 of the population in the UK 
and other countries in Europe (59), over 500,000 carries the disease in the united state, 
the incidence of Crohn’s disease is increasing worldwide (25). CD is not a sex or race 
related, frequently affects people between the ages of 16 and 25, but it can also occur in 
early childhood or later in life. CD can affect any part of the gastrointestinal tract 
inflamed segments are discontinued in form of patches separated by normal bowel. 
Inflammation is transmural resulting in fistula formation and the most common location 
is the ileum and small bowel (32). CD Prevail in two distinct forms in which it is 
analogous to two other mycobacterial diseases, leprosy and tuberculosis: a perforating 
form and a non-perforating form (27, 33, 43). Leprosy and tuberculosis both manifest in 
two distinct clinical forms: a contained form and an aggressive form (28, 61, 64).  UC, in 
contrast to CD, is a condition in which the inflammatory response is restricted to the 
colon. Inflammation is limited to the mucosa and is continuous with ulceration and 
edema.  The etiology of any of these two disorders remain unknown, however granuloma 
and pathologic manifestations in CD resemble aspects found in mycobacteria-caused 
diseases such as tuberculosis, leprosy and paratuberculosis ( 16, 53, 8). MAP has been 
reported as possible causative agent for CD, this possibility is increasingly gaining 
momentum due to the recent findings, MAP was isolated from blood, tissue, milk of CD 
patients (7, 46, 47). Early studies had shown that MAP is resistant to killing by 
macrophages and/or Polymorphonuclear cells (44) 
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        In 2001, three research groups had reported that three different mutations in NOD2/ 
CARD15 gene are associated exclusively with CD (31; 35, 49). the first susceptibility 
gene for Crohn’s disease was then  identified: NOD2 (nucleotide-binding oligomerization 
domain) better known as CARD15 (Caspase activation recruitment domain) gene 
annotated as  NOD2/CARD15 is expressed as cytoplasmic protein in monocytes, and it is 
comprised of N-terminus caspase-activation recruitment domains (CARD), a central 
nucleotide- binding domain, and a C-terminus leucine-rich repeat (LRR) domain. When 
The LRR domain senses muramyl dipeptide (MDP), the minimal motif of bacterial cell 
wall peptidoglycan, CARD15 will activate NFkB. It is also known that NOD2/CARD15 
is regulated by inflammatory cytokines, such as TNFalpha and IFN-gamma. Mutations in 
NOD2/CARD15 were associated with CD, suggesting a role for intracellular pathogen-
host interactions in the etiology of the disease.  
        Medical application of Microarray A study done by Whitney et al. provides a strong 
support for the feasibility of   RNA Microarray analysis of gene expression patterns in 
peripheral blood as a basis for detection and diagnosis of disease in humans. This study 
showed that the degree of variation in gene expression in the blood of healthy individuals 
is smaller than the one seen in the individuals who had cancer or infection (62). An RNA 
Microarray analysis of the expression profile of genes from CD and UC patients using the 
buffy coats from peripheral blood had shown that 5630 genes (17% of total number of 
genes) were differentially expressed in both IBD disorders 200 of which were genes 
involved in immune response. Interestingly enough, the study showed that IFNGR1 
(interferon-gamma receptor) gene, which encodes the ligand-binding chain of the IFN-
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gamma receptor, is Downregulated exclusively in CD patients. In this study, we 
evaluated the expression of IFNGR1 gene using quantitative real time RT-PCR in an 
attempt to confirm the Microarray findings. Numerous studies had shown that 
deficiencies in IFNGR1 gene are associated with familial disseminated atypical 
mycobacterial infection and disseminated BCG infection. Individuals carrying these 
deficiencies have an immunologic defect predisposing them to infection with 
mycobacteria (38, 39, 40). If confirmed our finding will add a strong argument to the role 
of MAP in CD etiology. 
        In this study, we intend to investigate blood samples from patients with CD, UC, 
NIBD and healthy controls for the presence of viable MAP using real time RT-PCR 
described in Chapter 1. The same clinical samples will be subjected to INFGR1 gene 
analysis using qRT-PCR investigating possible downregulation as shown previously in 
our lab using microarray chip analysis.  Ultimately the study will provide for the first 
time weather there is a link between the INFGR gene downregulation and susceptibility 
to MAP infection in patients with active Crohn’s disease. 
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Materials and methods 
Patient Selection and Specimen Source  
        A total of 18 subjects consisting of 6 CD, 2 UC and 10 NIBD were included in this 
study. Informed consent was obtained from the subjects in accordance with Institutional 
Review Board regulations at the University of Florida, Gainesville VAMC, and the 
University of Central Florida. The diagnosis of CD or UC was established on standard 
clinical, endoscopic, histologic, and radiographic criteria (3). One whole blood sample 
drawn into a K -EDTA sterile Vacutainer
® 
2
tube was collected from each subject. All 
samples were coded and a self-reported health status and medication use of each subject 
was recorded using a standardized questionnaire in order to minimize variables such as 
age, gender, and medication interference.  
Peripheral Blood Withdrawal and Processing  
        The samples were immediately processed in a class II biosafety cabinet. For buffy 
coat extraction, the tubes were centrifuged at 3000 rpm for 10 min. The buffy coat layer 
from each tube was transferred into an RNase-free tube containing 750 ul of RNA later 
solution (Ambion, CA) and kept at 4oC until processing.  
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RNA extraction:  
        Total RNA was isolated from Buffy Coats using modified protocol from 
RNAqueous-4PCR Kit (Ambion, CA).whole blood was centrifuged at 3000 rpm for 10 
min, buffy coat layer was then transferred into a 2ml RNase free tube containing 750 ul 
of RNA later then processed immediately by centrifugation at 13000rpm for 1 minute , 
cell pellet was treated with lysing solution and Nucleic acid was separated using phenol 
chlorophorm the aqueous phase was then transferred to new RNase free 2ml tube RNA 
was washed, eluted then treated with DNase I for 30 min at 37oC. The RNA purity and 
integrity was assessed by Agarose gel and stored at -80oC to be reverse-transcribed.  
cDNA Analysis:  
        The RNA isolated from buffy coats was subjected to reverse transcription using the 
super script III kit (Envitrogen, CA) as described in Chapter 1. The cDNA was then used 
for evaluation by real time RT-PCR. 
Quantitative Real time RT-PCR: 
        A real time RT-PCR was optimized and normalized to evaluate quantitatively the 
gene IFNGR1 using syber green and MyIQ system (BioRad, CA), 12.5ul of SYBR Green 
mix were added to MgCl2 (5mM), Betaine (0.5mM), primers (6 mM), 2.5ul of cDNA, 
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and sterile distilled water to a final volume of 25ul into sterile PCR tube and were 
incubated at 95oC for 5 min as hot start step followed by 40 cycles : 20 sec denaturation 
step at 95oC then 30 sec annealing step at 60oC were the Fluorescence was captured for 
analysis. Primers were designed with Primer 3 software and blasted against the gene bank 
data base for specificity; we used Primers MI1/MI2 that amplifies 200bP from the 5’ end 
of the gene. The IFNGR1 gene is GC rich, 
MI1: 5’CCCCTTGTCATGCAGGGTGTGA 3’ 
MI2: 5’ CAGGGACCTGTGGCATGATCTGG 3’ 
        To avoid secondary structures, Betaine was added as described in Chapter 1.  B-
actine was used in order to normalize the reaction as reference gene and the results were 
analyzed. 
IFN gamma ELISA Test: 
        Interferon gamma was evaluated in sera and plasma from patients with CD, UC and 
from NIBD individuals using an interferon gamma based ELISA kit (R&D Systems, 
Minneapolis, MN). Assay Diluent was added to each well in the ELISA plate, followed 
by Standards, samples, and control as described by the manufacturer. Microtiter plates 
were incubated for 2 hours at room temperature, followed by washes as described in the 
kit. IFN-γ Conjugate was added to each well. The plates were then incubated for 2 hours 
at room temperature, washed again and then incubated in the dark for 30 min. in the 
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presence of substrate solution. The optical density of each well was determined using a 
microplate reader set to 450 nm and 570 nm. Reading at 570nm was then subtracted from 
reading at 450nm in order to correct optical imperfections in the plate. 
Results 
        To evaluate the expression of IFNGR1 gene, RNA samples isolated from buffy coats 
of 6 CD patients and 2 UC subjects were analyzed against RNA from buffy coats of 10 
NIBD individuals (4 of them were healthy individuals). A quantitative real time RT-PCR 
was developed and optimized for this purpose. The results were compared to microarray 
outcomes from previous study done on the same samples. cDNA of IFNGR1 gene was 
sequenced for mutation analysis. 
Quantitative real time RT-PCR:         
        Isolated RNA was evaluated using quantitative real time RT-PCR assay developed 
and optimized for this purpose. The assay was normalized using β-actine gene as 
reference gene. Primers used were specific for IFNGR1 gene and amplify a 200 base pair 
from the 5’ end of the gene and specificity of sequence amplified was assisted using melt 
curve analysis. As shown in Table 8 a and b, all 10 (100%) NIBD subjects including 4 
healthy controls expressed normal and expected level of IFNGR1 gene. Normal gene 
expression was also observed in both (100%) patients with UC. However, out of the 6 
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CD patients, 5 (83%) showed defect in the INFGR1 gene expression suggesting a 
possible downregulation. Only one CD (17%) patient showed normal INFGR1 gene 
expression. Our findings also confirmed the microarray analysis data which showed that 
the IFNGR1 gene is exclusively downregulated in CD patients. This could give a strong 
insight to the role of Map in CD since IFNGR1 defect was associated with Mycobacterial 
infection (12, 36, 37, 38). Interestingly, evaluation of buffy coat from the patient who 
expressed IFNGR1 gene normally, with culture and nested PCR as well as with real time 
RT-PCR confirmed presence of MAP in blood samples of this patient (table9). An 
IFNGR1 gene mutation analysis for samples from this patient is undergoing for further 
investigating the gene and its role in MAP infection.    
Evaluation of levels of IFN-γ in Clinical Sera: 
        Along with Downregulation analysis, sera from CD and UC patients as well as from 
NIBD individuals were analyzed to evaluate the level of IFN-γ in blood. Table 10 
illustrates data from an ELISA analysis and as expected shows clear increase in 
concentration of IFN-γ in sera from the majority of CD patients (5/6; 83%), 1/2 (50%) of 
UC patients and 0/5 of healthy individuals.  
        One UC and one CD patients presented a normal level of IFN-γ this could be 
explained by the antimycobacterial treatment they followed. Interestingly, the patients 
with higher concentration of IFN-γ had downregulated IFNGR1 gene. 
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 Discussion 
 
        IFNGR1 gene encodes the ligand binding chain alpha of the IFN-γ receptor. As 
shown in this study, using real time RT-PCR, IFNGR1 was downregulated exclusively in 
patients with CD but not in UC patients. This data confirm what we had found earlier by 
microarray analysis (figure15). And correlate with theory that associate MAP with CD (7, 
33, 28, 46). Downregulation of IFNGR1 gene may cause a failure of IFN-γ to up-regulate 
production of TNF-α by macrophages hence disregulation of antigen processing and 
presentation (48) even if IFN-γ concentration in plasma from patient with CD and UC is 
relatively higher as shown by data from ELISA Table 10 
        In 1996, Newport et all revealed in a case study that deficiency in IFNGR1 
expression due to mutation lead to a defect in immune response in patients carrying this 
mutation predisposing them to mycobacterial infection. Our finding, correlate with 
Newport study and suggest strongly a host susceptibility condition for establishing a 
mycobacterial infection. It also support why UC patients having MAP exposure don’t 
develop the same clinical manifestations as CD patients or don’t respond to anti-
mycobacterial treatments.  Preliminary data from the ELISA measurement of interferon 
gamma level in clinical sera were not surprising. It is well known that INF-γ level is 
elevated in inflammatory bowel disease patients. The significance of this observation is 
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important in order to associate that with downregulation of the gene encoding for the 
receptor of INF-γ.  Although, this study is still in the early stages, it clearly indicates the 
need for a large scale investigation of the susceptibility of the INFGR1 gene in CD 
patients. We believe we may just have discovered the genetic susceptibility factor in 
hosts with Crohn’s disease. 
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CHAPTER FOUR: GENERAL DISCUSSION 
         
        Association of MAP with CD has been subject of vigorous debate among scientists, 
Evidence supporting a link between Map and Crohn’s disease such as higher detection 
rates of Map by PCR and culture in clinical samples from Crohn’s patients compared 
with controls; detection of anti-MAP IgG antibodies in sera from CD patients and anti-
Map antibiotic therapy resulting in remission, or significant improvements, in many 
cases. The general opinion among the scientific community is that there isn’t enough 
evidence to prove or deny the role of MAP in CD etiology; nevertheless, the hypothesis is 
still valid. The etiology of CD had been controversial; many agents were reported to have 
a role in this etiology; thus, Crohn’s disease is now believed to have a multifactorial 
etiology with involvement of genetic predisposition (NOD2 mutations), environmental 
factors (infectious agent, diet or smoking), and abnormal inflammatory response (25).  
        Isolation and culture of MAP from clinical samples from CD patients have been 
tried in the past. The outcome depended significantly on the technology used and the 
specimen selection and processing.  We previously reported the isolation of MAP from 
full-thickness tissue samples obtained from CD patients, from Breast milk and from 
blood samples from CD patients following short term incubation in mycobacterial growth 
indicator tube (MGIT) culture media (46,47). In all reports, MAP presence in the culture 
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was evaluated using IS900-based PCR. 
        As reported by Chiodini, MAP in CD clinical samples is in Spheroplastic form (cell-
wall deficient form) which is different from those in animals with JD this contribute 
greatly to the challenges faced when culturing MAP from Clinical samples from CD 
patients (7); using technology designed for isolation of bacillary form of MAP as in JD 
sources may not be applicable to that in human with CD. That alone will play a major 
factor in the outcome of the study.  There is a possibility that exposure to MAP could 
occur through environmental fecal contamination or from the milk or blood from JD-
infected animals which can explain isolation of MAP from NIBD individuals (20, 23, 24, 
25).  
        Development of Real time RT-PCR that detect IS900 MAP specific sequence will 
eventually aid other conventional techniques such as culture media, despite the need for 
long term incubation, in rapid detection of viable MAP in clinical samples. Most 
importantly, the application of this technology will significantly aid the elucidation of 
MAP role in Crohn’s disease pathogenesis. Regardless of the outcome, this test may aid 
in resolving the MAP debate in Crohn’s disease etiology. 
        The preliminary data of this study along with microarray data suggest that 
downregulation in INFGR1 gene and the detection of viable MAP together in CD 
patients provide yet the strongest evidence toward the linkage between MAP and CD 
etiology. It also supports why UC patients having MAP exposure don’t develop the same 
clinical manifestations as CD patients or don’t respond to anti-mycobacterial treatments. 
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 APPENDIX A: FIGURES 
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M        1                  2                3        4 
 
                      
10Kb__ 
2Kb___ 
 
Figure1: comparison of RNA yield with Qiagen protocol, Modified Qiagen protocol 
and combination of Mechanical and chemical extraction. 
 RNA samples were mixed with sample loading buffer and analyzed on 1% agarose gel 
electrophoresis. M: marker, lane 1 corresponds to RNA extraction from manufacturer 
protocol, Lane 2 corresponds to RNA extraction from modified manufacturer method, 
and lane3 & 4 correspond to RNA extraction using combination of physical disruption 
and chemical extraction. 
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3Kb 
1Kb 
 
Figure 2: Evaluation of RNA extracts for the presence of DNA using DNase 
treatment using agarose gel electrophoresis.  
 RNA extracts isolated using our modified procedure was treated with DNase for 30 min 
at 37o C. 
Band 1 corresponds to 23S ribosomal RNA; Band 2 corresponds to 16S ribosomal RNA 
 
43 
 
  
 
                                      
 
300bp___ 
200bp___ 
 
Figure3:  Evaluation of RNA extracts for the presence of DNA in the presence and 
absence of DNase using PCR analysis. M 1 2 3
 M: corresponds to marker. Lane 1 corresponds to negative controls; Lane 2 corresponds 
to PCR product using RNA without DNase treatment, Lane 3 corresponds to PCR using 
RNA with DNase treatment as template.     
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                               M        1          2          3          4         5          6         7 
                         
 
400bp___ 
200bp---- 
 
Figure 4: Evaluation of the RNA extracts for the presence of MAP DNA in the 
presence and absence of cDNA synthesis step. 
 M corresponds to Marker, Lane 5&6 corresponds to RNA extracts treated with DNase 
and then subjected to cDNA synthesis before RT-PCR was employed. Lane 3 same as 3 
except the cDNA synthesis step was eliminated. Lanes 1 and 2 corresponds to negative 
control where templates were not included in the PCR amplification. Lane 7: corresponds 
to positive control where DNA template was used.  
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Figure 5 Evaluation of our real-time RT-PCR for specific detection of MAP. RNA 
templates from 4 different microorganisms were subjected to real-time RT- PCR analysis 
using our developed protocol. A corresponds to graphical illustration of the real time 
PCR and B corresponds to agarose gel electrophoresis of PCR products shown in figure 
5-I, the green color corresponds to tunes containing MAP cDNA. The blue, red and 
yellow correspond respectively to MAV, MTB and MSM. IN Figure 5-II, lane 6 
corresponds to tunes containing MAP cDNA, lane 1 and 2 correspond to negative 
controls, lane 3 corresponds to MSM, lane 4 corresponds to MTB and lane 5 correspond 
to MAV.   
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Figure 6: Effect of annealing Temperature on secondary structure formation in 
IS900 sequence. 
Alignment of IS 900 sequence:  A: at 55oC, B: at 60oC, C: at 69oC 
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                                                          Cycle 
1    2       3 4       5    6      7     
            II)         M      1      2       3      4       5       6        7      8      M 
                       
150 bp____ 
 
 
 
  
 
  
 
 
 
 
 
Figure 7: Optimization of the concentration of Oligonucleotide primers used in this 
study. A serial dilution of F/R1 primers ranged from (0 to 33 pmol/ul; lanes 2-8) were 
evaluated by real time RT-PCR. Curve7 correspond to a primer concentration of 
6pmole/ul M: corresponds to Marker, Lane 1 corresponds to negative control.  
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165 
bp 
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Figure 8: evaluation of the annealing temperature used in this study:  
figure8-I corresponds to Real time RT-PCR Graph, where curves a to h : corresponds to 
reaction with annealing temperature that varies from 54oC to 64oC,curve I corresponds to 
negative control. In figure 8-II, M corresponds to marker, lane 1 corresponds to negative 
control, and lane 2 to 9 correspond to reactions with annealing temperature from 54oC to 
64oC 
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165bp 
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Figure 9: Optimization of the concentration of MgCl2 used in this study. 
 A serial concentrations of MgCl2 from (0 to30 mM; lanes 1-7) were evaluated by real 
time RT-PCR. M: corresponds to Marker.  
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Figure 10: Evaluation of our real-time RT-PCR for sensitive detection of MAP 
RNA. 
 Dilution series from 1:10 to 1:1000000 of RNA templates with a starting 
concentration of 33ng/ul were subjected to real-time PCR analysis using our 
developed protocol: Figure10-I) corresponds to graphical illustration of the real time 
PCR. Letters from a to g corresponds respectively to tunes containing MAP RNA in 
respectively 1 to 1:1000000 dilutions. Figure10-II) corresponds to agarose gel 
electrophoresis of PCR products shown in figure 10-I, lanes 1 to 7 corresponds to 
tunes containing MAP RNA , lane 8 correspond to negative control, lane 1 to 7 
correspond to PCR products from  RNA dilutions with 1 been RNA with no dilution 
and 7 been RNA with the higher dilution. M corresponds to marker.  
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                                                                          Cycle 
Figure11: Representative figure for evaluation of samples from patients using real 
time RT-PCR 
Each sample is represented by different color according to its position on the plate. 
Standards were used in this assay as well as controls.  
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Figure 12: Detection of MAP in human samples by Real time RT-PCR   (12hours) 
and culture confirmed by nested PCR (12weeks). 
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Figure13: Evaluation of MAP positive samples from CD, UC and NIBD individuals 
using real time RT-PCR compared to culture confirmed by nested PCR 
 
 
 
 
 
 
  
 
  
 
 
Figure 14: Biological themes predicted by MeV with EASE microarray analysis 
software 
We found that 17% (5630 genes) of the total number of genes was differentially 
expressed in both IBD disorders compared to the reference pooled sample. These genes 
were distributed mainly within four biological themes classified as cellular processes 
(38%), physiological processes (26%), intracellular genes (18%), and genes involved in 
metabolism (18%). (This figure was obtained from Doctor Romero PhD thesis) 
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Figure 15:  variation in some of the immune response gene expression patterns 
including IFNGR1 in human white blood cells.  
The differentially expressed genes IFNGR1 is boxed in red  and indicated by a plus sign 
next to the red box. Each element is red, green, black, or gray. Black elements have a log 
ratio (Cy5/Cy3) of 0, while green elements have a log ratio of less than 0 and red 
elements have a log ratio greater than 0. The further the ratio from 0, the brighter the 
element is. Gray elements have invalid values and are not used in any analysis. 
(This figure was obtained from Doctor Romero PhD thesis)  
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III) 
 
 
Figure 16: Representative figure for IFNGR1 gene expression analysis using real 
time RT_PCR.  
I) correspond to real time RT-PCR graph, II) correspond to representative gel picture and 
III) correspond to melt curve which show 2 peaks, one for IFNGR1 around 81oC and 
another one around 90oC for beta-Actine. 
N: correspond to negative controls, P corresponds to positive control, and M corresponds 
to marker, in the graph each sample is represented by distinguished color 
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∆Ct
        ______________NIBD____________   _UC_  ______CD_________ 
 
 
Figure17: graph illustrating quantitative real time RT-PCR data 
The higher the ∆Ct the lower is the expression. 
 Figures 1 to 10 correspond to NIBD samples, figures 11 & 12 correspond to UC samples 
and figures 13 to 18 correspond to CD samples  
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Table1: List of microorganisms used in the study. 
 
Microorganism Strain 
Mycobacterium avium subspecies 
paratuberculosis 
Mycobacterium avium subspecies avium 
Mycobacterium tuberculosis 
Mycobacterium smegmatis 
ATCC Ben 
 
Clinical isolate strain LM1 
ATCC 25177 
MC2155 
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Table2. Oligonucleotide primers used in this study. 
 
Nucleotide sequence                                               Primer’s name     Reference 
5’ GTT-CGG-GGC-CGT-CGC-TTA-GG-3' 
5’ GAG-GTC-GAT-CGC-CCA-CGT-GA-3’ 
5’ ATGTGGTTGCTGTGTTGGATGG 3’ 
5’CCGCCGCAATCAACTCCAG 3’ 
5’ CACGTCGGCGTGGTCGTCT 3’ 
5’ CGTCACCGCCGCAATCAACT 3’ 
P90 
P91 
AV1 
AV2 
F1 
R1 
(31, 33, 35) 
 
 
 
In this study 
In this study 
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Table 3: Optimized protocols for PCR analysis used in this study:         
 
Conditions                        conventional Nested PCR                 Real time RT-PCR  
 
 
 Thermal cycler                                  iCycler                                                            My IQ system 
Reaction duration                                     2X 3 h                                                             1:00 h 
Reaction volume                                       50 ul                                                                 25 ul 
Analysis                                             gel electrophoresis                                          real time fluorescence 
Amount analyzed                                    5 ul (10%)                                                      25 ul (100%) 
Target/size                                         IS900 /(400 bp)                                                IS900 /(165 bp) 
Primers/concentration.                     P90, 91/(12 pmole/ul each)                             F1/R1/(6 pmole/ul each) 
                                                           AV1/AV2 (10pmole/ul)     
MgCl2 conc.                                           4 ul (5mM)                                                       1ul (5mM)                                            
PCR buffer                                       5ul [200mM Tris-HCl (pH8.4),                     12.5ul (Buffer, dNTP   
                                                         500mM KCl]                                                  & enzyme all mixed 
                                                                                                                                 in one tube) 
dNTP concentration                          1ul (10mM) 
DNA polymerase                              HiFi Taq polymerase (5U/ul) 
PCR parameters                               hot start: 5 min/95 oC                            hot start: 3 min/95ojC 
                                                         36 cycles: 45 s/95 oC                             40 cycles: 10 s/95 oC 
                                                                          45 s/62 oC                                              30 s/60 oC 
                                                                          120 s/72 oC 
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Table 4A: Analysis of culture samples For MAP by real time RT-PCR versus 
culture and nested PCR. 
 
Sample Code Diagnosis Real time RT-PCR Culture& Nested PCR 
B2 CD Positive Positive 
B3 CD Positive Positive 
R14A CD Positive Positive 
R14B CD Positive Positive 
B20 CD Positive Positive 
R33B CD Negative Negative 
UCF6 CD Positive Positive 
UCF7 CD Positive Positive 
UCF8 CD Positive Positive 
B34 CD Positive Positive 
B50 CD Positive Positive 
B55 CD Negative Positive 
R60B CD Negative Negative 
Total 13 10/13(77%)  11/13(85%)  
B39 UC Negative Negative 
Total  1    0/1 0/1  
R6 NIBD Negative Negative 
B30 NIBD Negative Negative 
R36 NIBD Positive Positive 
Total 3   1/3 (33%) 1/3 (33%)  
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Table 4B: Over all summaries of MAP detection in culture samples by direct 
analysis using real time RT-PCR versus culture and nested PCR. 
  
 
Patients 
Diagnosis 
MAP positive  by 
real time RT-PCR
MAP positive by 
culture & nested PCR 
CD 10/13(77%) 11/13(84%) 
UC 0/1(0%) 0/1(0%) 
NIBD 1/3(33%) 1/3(33%) 
Total 11/17(65%) 12/17(70%) 
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Table5A: Analysis of peripheral blood buffy coat samples for Map detection by real 
time RT-PCR versus culture and nested PCR. 
 
Sample code Diagnosis Real time RT-PCRc Culture & Nested PCRd
BS77 CD Negative Negative 
BS78 CD Negative Negative 
BS82 CD Positive Positive 
BS88 CD Positive Positive 
BS92 CD Positive Positive 
BS96 CD Negative Negative 
BS99 CD Negative Negative 
Total 7 3/7(42%) 3/7(42%) 
BS94 UC Positive Positive 
BS95 UC Positive Positive 
Total 2 2/2(100%) 2/2(100%) 
BS72 NIBD Positive Positive 
Bs73 NIBD Negative Negative 
BS74 NIBD Positive Negative 
BS75 NIBD Negative Negative 
BS76 NIBD Negative Negative 
BS79 NIBD Negative Negative 
BS83 NIBD Negative Positive 
BS84 NIBD Negative Positive 
BS85 NIBD Negative Negative 
BS86 NIBD Negative Positive 
BS87 NIBD Negative Negative 
Total 11 2/11(18%)  4/11(36%)  
NS Healthy Negative Negative 
MC Healthy Negative Negative 
Md Healthy Negative Negative 
Bn Healthy Negative Negative 
Total 4 0/4 (0%) 0/4 (0%) 
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CD: corresponds to patients with Crohn’s disease 
UC: corresponds to patients with ulcerative colitis 
NIBD: corresponds to individuals with non-inflammatory bowel diseases. 
RT-PCR was performed using R1/F1 oligonucleotide primers 
dbuffy coats were inoculated into MGIT (MYCOBACTERIA GROWTH INDICATOR 
TUBE ) culture media, incubated for a minimum of 12 weeks and then confirmed for 
MAP using nested PCR based on the p90/91 oligonucleotide primers. 
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Table 5B: Over all summaries of MAP detection in peripheral blood buffy coat 
samples by direct analysis using real time RT-PCR versus culture and nested PCR. 
 
Patients 
diagnosis 
 MAP Positive 
by Real time RT-
PCR 
MAP Positive by 
Culture & Nested 
PCR 
Real time RT-PCR 
versus culture & Nested 
PCR 
IBD             
CD 
3/7(42%)  3/7(42%)  100% 
                
UC 
2/2(100%)  2/2(100%)  100% 
Total 5/9(55%) 5/9(55%)  
NIBD  2/11(13%)  4/11(26%)  50% 
Healthy 0/4(0%) 0/4(0%) 100% 
Total 2/15(13%) 4/15(26%)   
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 Table 6: Analysis of fresh tissue samples for MAP detection using real time RT-PCR 
versus culture and nested PCR.  
 
Sample 
Code 
Diagnosis Real time RT-
PCR 
Culture & Nested 
PCR 
R61A CD, inflamed 
tissue 
positive Pending 
R61B CD, non-
inflamed 
negative Pending 
R62A CD, inflamed Negative Pending 
R62B CD, non-
inflamed 
negative Pending 
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Table7: Genes with Differences in the Expression Levels in each subtype of IBD 
Disorder. (This table was used from doctor Romero PhD thesis). 
______________________________________________________________________  
Gene Bank            Description                                        Expression in       Expression in  
                                                                                        CD patients          UC patients  
______________________________________________________________________  
AA083407         Tripartite motif-containing 22              No change              Downregulated  
AA476221         Unnamed protein product                   Downregulated        No change  
AA495985         Small inducible cytokine                     Downregulated       Upregulated  
                           A18 precursor (CCL18) 
AI123732          EBV-induced G protein-coupled         Downregulated         No change  
                           receptor 2 (EBI2) 
AA281497      Interferon-gamma receptor alpha 1      Downregulated          No change  
R47893           Small inducible cytokine A3                 Downregulated         Upregulated 
                        precursor (CCL3)   
AA454646     Lymphotoxin-beta receptor                   No change                 Upregulated  
AI298976      Lymphotactin precursor (XCL1)            Downregulated          No change  
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Table 8 a: Analysis of Buffy coats from peripheral blood of patients to 
evaluate IFNGR1 gene expression using quantitative real time RT-PCR 
Sample 
code Diagnosis 
microarray 
RT-PCR 
 
    
Gene expression ∆Ct Gene expression 
BS 25 Healthy 
Normal 4.42 Normal 
BS 26 Healthy 
Normal 3.23 Normal 
BS 27 Healthy 
Normal 4.38 Normal 
BS 28 Healthy 
Normal 5.62 Normal 
BS54 NIBD 
No data 
4.61 
Normal 
BS83 NIBD 
No data 6.28 Normal 
BS84 NIBD 
No data -0.53 Normal 
BS85 NIBD 
No data 4.33 Normal 
BS86 NIBD 
No data 2.46 Normal 
BS87 NIBD 
No data 2.61 Normal 
BS 33 UC 
No change 
5.33 
No change 
BS47 UC 
No change 
6.09 
No change 
BS 35 CD 
Down-regulated 14.31 Down-regulated 
BS 37 CD 
Down-regulated 11.56 Down-regulated 
BS 42 CD 
Down-regulated  10.19 Down-regulated 
BS 43 CD 
Down-regulated 13.78 Down-regulated 
BS61 CD No change 1.87 No change 
BS88 CD No change 11.31 downregulated 
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 Table 8b: overall Summary of IFNGR1 gene expression in CD patients and Non CD 
individuals. 
 
 
Patients Diagnosis down-regulated gene  
NIBD 0/10(0%) 
UC 0/2 (0%) 
CD 5/6(83%) 
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 Table9: Evaluation of IFNGR1 gene expression in with regard to MAP diagnosis in 
samples from CD, UC and NIBD subjects. 
 
 
Sample's code Diagnosis Q RT-PCR MAP  
    Analysis Diagnosis 
BS25 NIBD normal negative 
BS54 NIBD normal negative 
BS85 NIBD normal negative 
BS87 NIBD normal negative 
BS33 
UC 
normal 
positive 
BS47 UC normal negative 
BS35 CD downregulated negative 
BS37 
CD 
downregulated 
positive 
BS42 
CD 
downregulated 
positive 
BS43 
CD 
downregulated 
positive 
BS88 CD normal positive 
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 Table 10: Evaluation of level of IFN-γ in sera from peripheral blood of CD, UC and 
NIBD subjects using ELISA: 
 
 
Sample  Diagnosis mean OD reading IFN-γ concentration Cut off value 
NS Healthy 0.09 12.5 
Normal 
MC Healthy 0.077 6 
Normal 
Md Healthy 0.083 9 Normal 
Bn Healthy 0.075 5 
Normal 
BS84 Healthy 0.067 1 
Normal 
BS33 UC 0.111 23 
Elevated 
BS47 UC 0.083 9 Normal 
R27 CD 0.087 11 
Normal 
R28 CD 0.785 360 
Elevated 
BS35 CD 0.108 21.5 
Elevated 
BS43 CD 0.11 22.5 Elevated 
BS44 CD 0.259 97 
Elevated 
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